🩺 ASH 2024: Triplet Regimens Achieve High Response Rates in Leukemias Three clinical trials led by MD Anderson Cancer Center researchers presented at ASH 2024 demonstrated high overall response rates and measurable residual disease (MRD) negativity in AML and CLL. Highlights include an

➡️ Check out our manuscript just published in AmericanJournalofHematology on Treated Secondary-AML: 673 patients, largest reported cohort 🔴 High-risk subtype: outcomes dismal, even in rare patients with fav genomics ✅ Warrants an independent prognostic designation 🔵 Ven improves outcomes in

🙏🙂 Very happy to share our manuscript on a granular analysis of a large cohort of Secondary Type AML with respect to contemporary therapies: ➡️ Clinico-genomic classification of AML ontogeny: Clinical secondary (CS), Genomic Secondary (GS) and Pure De novo (DN) AML🧬 ➡️ GS-AML

@ CDiNardo Naval Daver, M.D. Sanam Loghavi, MD صنم لغوی 🔬🧬 Tapan Kadia Jen Marvin-Peek, MD Mrinal Patnaik Fadi Haddad, MD Naveen Pemmaraju, MD Nicholas Short MD Vikram Mathews Danielle Hammond, MD Patrick Reville, MD, MPH Mahesh Swaminathan Gautam Borthakur G Garcia-Manero

Updated results of our frontline trial of FLAG-IDA+VEN, showing CRc in 95% of newly diagnosed #AML. Responses were seen across all ELN22 risk groups, w/ 90% MRD neg. In RR AML, 79% first salvage & TP53wt attained CRc. MD Anderson Cancer Center rdcu.be/ebcvm Leukemia Journal

🙂 Very Happy to share this comprehensive review on AML, from an MD Anderson Cancer Center perspective, discussing all that is new and exciting in the field 🩸 Hagop Kantarjian,MD ➡️ Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges ACS

New publication, online now @BloodJournal Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes Bofei Wang Jen Marvin-Peek, MD Hussein Abbas ashpublications.org/blood/article/…

Amazing! Congratulations to my friend and co-fellow Nazli Dizman 🎉

➡️ Rates of HSCT and Upset bar plot showing barriers to HSCT in frontline TP53-mut AML

MD Anderson (MD Anderson Cancer Center) Research Highlights Boyi Gan, PhD Steven H. Lin Hussein Abbas Ivo Veletic, MD Naval Daver, M.D. Jayastu Senapati Krina Patel Gisele Tlusty oncodaily.com/insight/md-and… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #CART #AML #CLL

Online Now! Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia dlvr.it/TKwjF7 #stemcells

So thankful to Conquer Cancer, the ASCO Foundation for the 2025 ASCO YIA! I am especially grateful to my amazing mentors and to MD Anderson Cancer Center for their unwavering support and guidance. Congrats to my fellow awardees. Proud to be a part of this inspiring group! #makingcancerhistory

👉 Check the Top #AML #abstracts at #EHA2025 by date and ID Many presented by our #Leukemia Faculty & Fellows from MD Anderson Cancer Center Looking forward to exciting discussions & new treatment options for patients at European Hematology Association OncoAlert AML Hub #leusm

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML. Co-authored by Jen Marvin-Peek, MD. Full article. brnw.ch/21wTx9F

Our #Opal bone marrow image is featured on the new Blood Journals Portfolio cover, highlighting the discovery of OSMR as a novel #AML biomarker. This work was led by Hussein Abbas, Patrick Reville, MD, MPH, Bofei Wang and Jen Marvin-Peek, MD at MD Anderson Cancer Center. Learn more: bit.ly/4d5MdC5

Acute myeloid leukemia remains one of the most heterogeneous hematologic malignancies, and accurate risk stratification continues to be a moving target. ow.ly/nykQ50WcXn0 #myeloidneoplasia

👉Here is an updated version of the Table which I initially posted post ASH2024. 👉Now Updated with EHA 2025 data including updated FLAIR, CLL13, CAPTIVATE trials. #CLL

👉👉👉Wonderful to meet up with the future leaders of leukemia research ! Naveen Pemmaraju, MD w/ Dr Alex Bazinet , Dr Wei Ying Jen & Dr Jen Marvin-Peek, MD | #leusm #MPNSM #BPDCN | #endcancer

👉👉👉Major new paper 📑 👉just out in BJH led by Dr .Wei Ying Jen & Dr .Tapan Kadia MD Anderson Cancer Center 📣 #MECOM fusion partner & bone marrow blast % influence outcomes of patients w/#MECOM -rearranged AML | Sanam Loghavi, MD صنم لغوی 🔬🧬 onlinelibrary.wiley.com/doi/10.1111/bj… #endcancer #leusm #MECOM

New publication 📝 A pooled analysis, published in Journal of Clinical Oncology, shows HMA + venetoclax + IDH inhibitor triplet regimen was well tolerated and improved outcomes in IC-ineligible patients with newly diagnosed IDH-mutated AML. Learn more: AML-Hub.com #AMLsm #leusm